Indivior PLC (IZQVF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in North Chesterfield, VA, United States. The current CEO is Mark Crossley.
IZQVF has IPO date of 2014-12-26, 1,000 full-time employees, listed on the Other OTC, a market capitalization of $2.89B.
Indivior PLC is a specialty pharmaceutical company that develops, manufactures, and markets buprenorphine-based prescription medications for treating opioid dependence and related disorders. The company's primary products include SUBLOCADE, an injectable formulation, and SUBOXONE, available in sublingual film and tablet forms, alongside legacy medications such as Temgesic and Buprenex. With operations spanning approximately 40 countries worldwide, Indivior focuses on addressing opioid use disorder, addiction, and co-occurring conditions through its product pipeline. Headquartered in North Chesterfield, Virginia, the company was established in 2014 and maintains research collaborations to advance its therapeutic offerings.
